Prelude Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Prelude Therapeutics Inc
Did you know?
Holds 2.2x more cash than debt — a strong balance sheet.
Current Price
$4.70
-10.13%GoodMoat Value
$0.97
79.4% overvaluedProfile
Valuation (TTM)
Market Cap$295.47M
P/E-2.97
EV—
P/B4.30
Shares Out62.87M
P/Sales24.34
Revenue$12.14M
EV/EBITDA—
Prelude Therapeutics Inc (PRLD) Stock Analysis
Market Cap$295.47M
Current Price$4.70
P/E Ratio-2.97
Forward P/E—
PEG Ratio0.06
EPS$-1.29
Book Value$1.09
P/B Ratio4.30
PRLD Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 21M
Revenue
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
7M
FY24
12M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
PRLD 52-Week Range
$0.76
$5.52
50-Day MA: $3.68200-Day MA: $2.10
Did you know?
Price sits at 83% of its 52-week range.
Prelude Therapeutics Inc (PRLD) Financial Summary
Prelude Therapeutics Inc (PRLD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $4.70 with a market capitalization of $295.47M.
Key valuation metrics include a P/E ratio of -2.97, price-to-book ratio of 4.30, and EPS of $-1.29. The company reports a profit margin of -819.6% and return on equity of -145.0%.
PRLD Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $295.47M |
| P/E Ratio | -2.97 |
| EPS | $-1.29 |
| P/B Ratio | 4.30 |
| P/S Ratio | 24.34 |
| Profit Margin | -819.6% |
| Return on Equity | -145.0% |
| Debt/Equity | 0.26 |
PRLD Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $0.00 | $-27.57M |
| FY20 | $0.00 | $-56.93M |
| FY21 | $0.00 | $-111.69M |
| FY22 | $0.00 | $-115.44M |
| FY23 | $0.00 | $-121.83M |
| FY24 | $7.00M | $-127.17M |
| FY25 | $12.14M | $-99.50M |
Prelude Therapeutics Inc (PRLD) Valuation
Based on GoodMoat's DCF model, Prelude Therapeutics Inc has a fair value estimate of $0.97. At the current price of $4.70, the stock appears 385.5% overvalued relative to our intrinsic value estimate.
PRLD Quality Indicators
Prelude Therapeutics Inc maintains a profit margin of -819.6% and an operating margin of -861.3%. Return on equity stands at -145.0%. The current ratio is 1.99. Debt-to-equity ratio is 0.26.
About Prelude Therapeutics Inc
Prelude Therapeutics Inc
PRLD Free Cash Flow
Prelude Therapeutics Inc generated $-56.37M in trailing twelve-month free cash flow, representing an FCF yield of -19.08%. This low FCF yield may reflect heavy reinvestment or growth spending.
PRLD Shares Outstanding
Prelude Therapeutics Inc has 0.06 billion shares outstanding at a share price of $4.70, giving it a market capitalization of $295.47M.